TY - JOUR
T1 - Methyl-substituted diindolylmethanes as inhibitors of estrogen-induced growth of T47D cells and mammary tumors in rats
AU - McDougal, A.
AU - Gupta, M. S.
AU - Morrow, D.
AU - Ramamoorthy, K.
AU - Lee, J. E.
AU - Safe, S. H.
N1 - Funding Information:
The financial assistance of the State of Texas Advanced Technology Program, the National Institutes of Health (CA64081) DAMD 17-99-1-93-96, and the Texas Agricultural Experiment Station is gratefully acknowledged.
PY - 2001
Y1 - 2001
N2 - Diindolylmethane (DIM) is formed by acid catalyzed dimerization of the phytochemical indole-3-carbinol, and both compounds inhibit formation and/or growth of mammary tumors in rodents. In this study, we have investigated the aryl hydrocarbon receptor (AhR) agonist activity and inhibitory AhR-estrogen receptor crosstalk induced by the following methyl-substituted DIMs: 1,1′-dimethyl-, 2,2′-dimethyl-, 5,5′-dimethyl-, 6,6′-dimethyl-, and 7,7′-dimethylDIM and 1,1′,2,2′-tetramethylDIM. The six compounds bound to the rat cytosolic AhR in a transformation assay but, at concentrations ≤ 10 μM, exhibited minimal to non-detectable AhR agonist or antagonist activities associated with CYP1A1 induction. In contrast, the methyl-substituted DIMs inhibited estrogen-induced T47D human breast cancer cell growth and the four most active compounds (1,1′-, 2,2′-, 5,5′-dimethylDIM and 1,1′,2,2′-tetramethylDIM) inhibited one or more estrogen-induced responses in the 21-day-old female B6C3F1 mice at a dose of 100 mg/kg/day (X3). Induction of hepatic CYP1A1-dependent activity was not observed at this high dose. The antitumorigenic activity of these compounds was examined in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor model in which the DIM analogs were orally administered (by gavage in corn oil) at a dose of 1 mg/kg/day (X10). 1,1′-DimethylDIM, 5,5′-dimethylDIM and 1,1′,2,2′-tetramethylDIM significantly inhibited mammary tumor growth, and this was not accompanied by changes in organ/body weights or histopathology. These studies demonstrate that methyl-substituted DIMs are selective AhR modulators (SAhRMs) with potential for clinical treatment of breast cancer.
AB - Diindolylmethane (DIM) is formed by acid catalyzed dimerization of the phytochemical indole-3-carbinol, and both compounds inhibit formation and/or growth of mammary tumors in rodents. In this study, we have investigated the aryl hydrocarbon receptor (AhR) agonist activity and inhibitory AhR-estrogen receptor crosstalk induced by the following methyl-substituted DIMs: 1,1′-dimethyl-, 2,2′-dimethyl-, 5,5′-dimethyl-, 6,6′-dimethyl-, and 7,7′-dimethylDIM and 1,1′,2,2′-tetramethylDIM. The six compounds bound to the rat cytosolic AhR in a transformation assay but, at concentrations ≤ 10 μM, exhibited minimal to non-detectable AhR agonist or antagonist activities associated with CYP1A1 induction. In contrast, the methyl-substituted DIMs inhibited estrogen-induced T47D human breast cancer cell growth and the four most active compounds (1,1′-, 2,2′-, 5,5′-dimethylDIM and 1,1′,2,2′-tetramethylDIM) inhibited one or more estrogen-induced responses in the 21-day-old female B6C3F1 mice at a dose of 100 mg/kg/day (X3). Induction of hepatic CYP1A1-dependent activity was not observed at this high dose. The antitumorigenic activity of these compounds was examined in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor model in which the DIM analogs were orally administered (by gavage in corn oil) at a dose of 1 mg/kg/day (X10). 1,1′-DimethylDIM, 5,5′-dimethylDIM and 1,1′,2,2′-tetramethylDIM significantly inhibited mammary tumor growth, and this was not accompanied by changes in organ/body weights or histopathology. These studies demonstrate that methyl-substituted DIMs are selective AhR modulators (SAhRMs) with potential for clinical treatment of breast cancer.
KW - Antitumorigenic
KW - Selective AhR modulators
KW - Substituted diindolylmethanes
UR - http://www.scopus.com/inward/record.url?scp=0035016018&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035016018&partnerID=8YFLogxK
U2 - 10.1023/A:1010608000074
DO - 10.1023/A:1010608000074
M3 - Article
C2 - 11437101
AN - SCOPUS:0035016018
SN - 0167-6806
VL - 66
SP - 147
EP - 157
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2
ER -